What is the uptake of the COVID-19 and influenza vaccines in people with severe mental illness?

Not Applicable

Active, not recruiting

• Conditions: Severe mental illness; COVID-19; Influenza; Vaccination; Mental Health - Schizophrenia; Mental Health - Psychosis and personality disorders; Mental Health - Depression; Public Health - Epidemiology; Mental Health - Other mental health disorders

• Registration Number: ACTRN12624000117516
• Lead Sponsor: HMRC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-02-08
• Last Update Posted: 19 February 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 2000000

Inclusion Criteria

Eligibility for exposure cohorts:

(i) COVID-19 exposure cohort: All individuals with SMI who were aged 18 years and over at 22/02/2021. We will define people as having SMI if they have been dispensed two prescriptions within 12 months for authority-only medications used specifically for SMI (ATC codes N05AH, N05AX, N05AE, N06AX) since 22/02/2019 (2 years prior to the period of interest of this study), or 2 prescriptions for lithium within 12 months. Authority-only medications will include all that were listed on the PBS during the time period (and subsequently may now be discontinued). In the case of quetiapine (ATC Code NO5AH04), we will only include anyone prescribed at least 100mg on those two occasions, to minimise the influence of off-label use.

(ii) Influenza exposure cohort: All individuals with SMI aged 18 years and over on 01/01/2018. We will define people as having SMI if they have been dispensed two prescriptions within 12 months for authority-only medications used specifically for SMI (ATC codes N05AH, N05AX, N05AE, N06AX) since 01/01/2016 (2 years prior to the period of interest of this study), or 2 prescriptions for lithium within 12 months. In the case of quetiapine (ATC Code NO5AH04), we will only include anyone prescribed at least 100mg on those two occasions, to minimise the influence of off-label use.

Eligibility for comparator cohorts:

(i) COVID-19 comparator cohort: A random sample of people on the Medicare Consumer Directory, randomly selecting a ratio of 4 random controls to every case from the entire population aged 18 years and over at 22/02/2021. This group will consist of people who have not been dispensed a prescription for one of the specified PBS medicines (ATC codes N05AH, N05AX, N05AE, N06AX) between 22/02/2019 to latest available.

(ii) Influenza comparator cohort: A random sample of people on the Medicare Consumer Directory, randomly selecting a ratio of 4 random controls to every case from the entire population aged 18 years and over on the 1st January in each of the years 2018 and 2019. This group will consist of people who have not been dispensed a prescription for one of the specified PBS medicines (ATC codes N05AH, N05AX, N05AE, N06AX) between 1/1/2016 to latest available.

Exclusion Criteria

None.

Study & Design

• Study Type: Observational
• Study Design: Not specified